Aquestive Therapeutics (NASDAQ:AQST) Coverage Initiated at Oppenheimer

Research analysts at Oppenheimer began coverage on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research note issued to investors on Monday, Marketbeat reports. The brokerage set an “outperform” rating and a $7.00 price target on the stock. Oppenheimer’s price target indicates a potential upside of 120.13% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on the company. Lake Street Capital dropped their price target on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 7th. Raymond James set a $7.00 price target on Aquestive Therapeutics in a report on Friday, March 7th. Alliance Global Partners reissued a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Thursday, May 15th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $10.14.

Aquestive Therapeutics Price Performance

AQST stock traded up $0.37 on Monday, reaching $3.18. The company’s stock had a trading volume of 2,087,963 shares, compared to its average volume of 1,511,884. Aquestive Therapeutics has a 52 week low of $2.12 and a 52 week high of $5.80. The company has a market capitalization of $315.86 million, a P/E ratio of -7.07 and a beta of 2.02. The firm has a fifty day moving average of $2.65 and a two-hundred day moving average of $3.15.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07). The company had revenue of $8.72 million during the quarter, compared to analysts’ expectations of $12.23 million. As a group, equities analysts expect that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Aquestive Therapeutics

Several institutional investors have recently modified their holdings of AQST. Summit Wealth & Retirement Planning Inc. purchased a new stake in Aquestive Therapeutics during the first quarter valued at about $29,000. Victory Capital Management Inc. bought a new stake in shares of Aquestive Therapeutics in the first quarter valued at approximately $31,000. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Aquestive Therapeutics during the 1st quarter valued at approximately $33,000. New York State Common Retirement Fund boosted its holdings in Aquestive Therapeutics by 713.3% in the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after buying an additional 10,700 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Aquestive Therapeutics in the 4th quarter valued at approximately $44,000. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.